Disulfiram-loaded hollow copper sulfide nanoparticles show anti-tumor effects in preclinical models of colorectal cancer

Biochem Biophys Res Commun. 2022 Dec 20:635:291-298. doi: 10.1016/j.bbrc.2022.10.027. Epub 2022 Oct 7.

Abstract

Colorectal cancer is one of the most common malignancies causing the majority of cancer-related deaths. There is an urgent need to develop new anticancer modalities. Recently, efforts have been made to turn clinically approved drugs into anticancer agents in specific tumor microenvironments via NPs. Disulfiram (DSF) as an effective copper (Cu2+)-dependent anti-tumour drug, which has been more widely used in antitumor research. Here, we constructed a novel therapeutic nanoplatforms, DSF@CuS, by encapsulating DSF in hollow CuS NPs to enable in situ chemoselective activation of DSF and hyperthermal amplified chemotherapy. The anticancer effect of DSF was enhanced by the thermal energy generated under NIR irradiation through the intrinsic photothermal conversion of CuS. As a result, significant apoptosis was induced in vitro, and tumor elimination was achieved in vivo. Collectively, DSF@CuS combined with photothermal therapy can significantly promote the apoptosis of CT26 colorectal cancer cells both in vitro and in vivo, providing a potential theoretical agent for the treatment of colorectal cancer.

Keywords: Colorectal cancer; CuS NPs; Disulfiram; Photothermal therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Cell Line, Tumor
  • Colorectal Neoplasms* / drug therapy
  • Copper / pharmacology
  • Disulfiram / pharmacology
  • Humans
  • Nanoparticles* / therapeutic use
  • Sulfides / pharmacology
  • Tumor Microenvironment

Substances

  • Disulfiram
  • cupric sulfide
  • Copper
  • Sulfides
  • Antineoplastic Agents